BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 8 Publications

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240

FEBS J, 2014, 281(17):3816-27

PubMed: 25040165

Virology, 2014, 450-451:182-95

PubMed: 24503081

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873

PLoS One, 2014, 9(11):e112014

PubMed: 25390891

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388

4 Customer Reviews

(A) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 μM) for 5 min, and this was followed by stimulation with 2-methylthio-ADP (2MeSADP) (50 nM) under stirring for 5 min. Western blots were then probed for phosphorylated Akt (Thr308), Akt (Ser473), glycogen synthase kinase 3b (GSK3b) (Ser9), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (Ser217/221), extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204), and cytosolic phospholipase A2 (cPLA2) (Ser505). The western blots shown are representative of three independent experiments.

J Thromb Haemost, 2018, 16(6):1211-1225. BX-795 purchased from Selleck.

Induction of basal p62 Ser403 phosphorylation in ULK1/2-deﬁcient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.

FEBS J 2014 281(17), 3816-27. BX-795 purchased from Selleck.
Virology 2014 450-451, 182-95. BX-795 purchased from Selleck.

Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 3.33 μM or 10 μM inhibitors (BX795 or CCT128930) in three-dimensional cell culture for 24 hours. Ten percent fetal bovine serum was used in A and B.

PLoS One, 2016, 11(5):e0155052. . BX-795 purchased from Selleck.

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW\X[I5TUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzZwODDuUS=>	Mn;1V2FPT0WU
KRX cells	MmniSpVv[3Srb36gZZN{[Xl?	NHTFWGo4KG2rboO=	M3e1c2lvcGmkaYTpc44hd2ZiU2XNU{11[WepZXSgWWxMOSBqdX7rco94diCxcnnnbY4qKGurbnHz[UBld22jaX6g[ZhxemW\|c3XkJIlvKEuUWDDj[YxteyC3c3nu[{BcOzKSXT3nZY1u[S2DVGCgZY5lKG27ZXzpckBj[XOrYzDwdo91\WmwIIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDdibXnudy=>	MV:yOlI4PTZ6MR?=
human NKM-1 cell	M3fB[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIDGSHBKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjF7NDFOwG0>	NUnuNI03W0GQR1XS
human P30-OHK cell	NVXCWI9ET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1T4cmlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7LDDJR\|UxRTBwNEm2OUDPxE1?	NFvsT4NUSU6JRWK=
human YH-13 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3jM[mlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=>	MVXTRW5ITVJ?
human LXF-289 cell	MnvvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVjne2dlUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:OC54NU[5N{DPxE1?	M1vVUXNCVkeHUh?=
human BE-13 cell	NV6zNo13T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEL0dWtKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44ODR5NzFOwG0>	M4jM[HNCVkeHUh?=
human RS4-11 cell	NGS5T4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFrSUJBKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJ3OUSg{txO	MVHTRW5ITVJ?
human A3-KAW cell	MnvKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXrJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|MxPTVizszN	NYDZd2RSW0GQR1XS
human PA-1 cell	M{HCcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkiwOFIzKM7:TR?=	MUPTRW5ITVJ?
human ES7 cell	NGG2ZXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHXSeYVKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPFM2PjZizszN	M3PVWXNCVkeHUh?=
human ES8 cell	NELBWJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkjLTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0N\|M3KM7:TR?=	NIHOVlZUSU6JRWK=
human SW982 cell	NFjxUHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD65OVEzPCEQvF2=	MVvTRW5ITVJ?
human VA-ES-BJ cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mnu3TY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh2Nkeg{txO	M2\IS3NCVkeHUh?=
human 697 cell	MnfqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH3afY9KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFE3OjNizszN	M13QOXNCVkeHUh?=
human MOLT-4 cell	MlnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFMzPDRizszN	M121PXNCVkeHUh?=
human D-283MED cell	M2nFbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVTPXHhUUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK4N21GTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMEO5OFgh\|pyv	NYXRXFNjW0GQR1XS
human ALL-PO cell	NULLRo9vT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFYxPzNizszN	M2TYOXNCVkeHUh?=
human NB14 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M374SWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFYxQDFizszN	M1H5PXNCVkeHUh?=
human NTERA-S-cl-D1 cell	NVvZeZZlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVPJcohq[mm2aX;uJI9nKGi3bXHuJG5VTVKDLWOtZ4wuTDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC3O\|c2KM7:TR?=	MWfTRW5ITVJ?
human BFTC-905 cell	MlHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn25TY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODhzMEGg{txO	MlP6V2FPT0WU
human H4 cell	NH7oemhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4HT[WlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkGwNlAyKM7:TR?=	MW\TRW5ITVJ?
human CHP-212 cell	MlzNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE1ODN5IN88US=>	NEK1OZVUSU6JRWK=
human A204 cell	NEfoZXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkG1OFY4KM7:TR?=	M2XBRnNCVkeHUh?=
human NB69 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4LBZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU5PjVizszN	MVXTRW5ITVJ?
human P12-ICHIKAWA cell	MmjjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2nyZmlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPFE4OSEQvF2=	MUTTRW5ITVJ?
human L-363 cell	M3;ZbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHTmRlhKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yQDF7NzFOwG0>	M3WyeXNCVkeHUh?=
human ES5 cell	MliwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NITCcYNKdmirYnn0bY9vKG:oIHj1cYFvKEWVNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVk{PTRizszN	M4PqNHNCVkeHUh?=
human CAL-51 cell	NIO3[4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWDLTnYxUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ{MUW2JO69VQ>?	NXq3coViW0GQR1XS
human NBsusSR cell	NYDMSVFWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGjXWFRKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ2NUe4JO69VQ>?	NUTDSWo3W0GQR1XS
human HOP-92 cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3nvcmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLUmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPzJ7MzFOwG0>	MUPTRW5ITVJ?
human DU-4475 cell	MonaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4\OXGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjl{NEWg{txO	NULu[oJtW0GQR1XS
human LB1047-RCC cell	NEi1c3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlzTTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK4NUDPxE1?	NYrzVIY{W0GQR1XS
human D-566MG cell	MnrrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFvVWmhKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyNES4JO69VQ>?	NWXlT3NPW0GQR1XS
human A375 cell	MmfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYjrXJNlUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODh3ODFOwG0>	M1zSOHNCVkeHUh?=
human ATN-1 cell	MlTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1jWZmlvcGmkaYTpc44hd2ZiaIXtZY4hSVSQLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM4OTh3IN88US=>	Mkf4V2FPT0WU
human M059J cell	NHXGSWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJG0xPTmMIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zO\|Y2OiEQvF2=	NFr5fnlUSU6JRWK=
human HSC-3 cell	M{O0ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGDPZY9KdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PDJyODFOwG0>	MXTTRW5ITVJ?
human DOHH-2 cell	M1vwPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGRQUEhvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFU5OTRizszN	MkDrV2FPT0WU
human G-402 cell	MkLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT60OlUzPSEQvF2=	NIDUcpBUSU6JRWK=
human LC-2-ad cell	NH;vT5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1LwTmlvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDdzM{Kg{txO	M1y5PXNCVkeHUh?=
human LOXIMVI cell	M3OxTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlUxPTV{IN88US=>	MmL0V2FPT0WU
human DK-MG cell	M3uzdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mkn2TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVczQThizszN	MX7TRW5ITVJ?
human HOS cell	MnHPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVe5VFV1UW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OzB7IN88US=>	NH[0SHBUSU6JRWK=
human BHT-101 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkLuTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Pzh5NzFOwG0>	MVPTRW5ITVJ?
human U-2-OS cell	NXH2fZp3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M170N2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42QDhyNjFOwG0>	MYrTRW5ITVJ?
human D-423MG cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxQDB4IN88US=>	NXOwZ\|BjW0GQR1XS
human AN3-CA cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYfxOoVsUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ\|OUmxJO69VQ>?	NVW1bXhUW0GQR1XS
human TE-11 cell	NELHOnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWjxd\|hQUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV{ODFOwG0>	NHPxZnhUSU6JRWK=
human SK-NEP-1 cell	NUH3XWp[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnLlTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV\|N{[g{txO	MV7TRW5ITVJ?
human MG-63 cell	MlnJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{TSfWlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY5PTZ5IN88US=>	M4q5WHNCVkeHUh?=
human RH-1 cell	MlnsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF\xNmJKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlcxOjd2IN88US=>	MoKzV2FPT0WU
human MDA-MB-157 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjdzNke0JO69VQ>?	Mnq0V2FPT0WU
human A427 cell	Ml\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlTjTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63N\|U5QSEQvF2=	NHSxRllUSU6JRWK=
human ES1 cell	NX;O[YpiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MojKTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke1OFUyKM7:TR?=	MorZV2FPT0WU
human C32 cell	M3;hc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVjjc5JOUW6qaXLpeIlwdiCxZjDoeY1idiCFM{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc3OzlizszN	NXHk[VlNW0GQR1XS
human LAMA-84 cell	M2W4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc3QDd{IN88US=>	MV\TRW5ITVJ?
human YKG-1 cell	NIfuVYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63O\|EzPCEQvF2=	MVzTRW5ITVJ?
human NCI-H1048 cell	MnvES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NELiTZZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{i1NFkh\|ryP	NGi3XHJUSU6JRWK=
human KS-1 cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{e4SmlvcGmkaYTpc44hd2ZiaIXtZY4hU1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFI6QCEQvF2=	NHWycFJUSU6JRWK=
human JVM-3 cell	NYT6TZpwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFHT[JlKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjR7MTFOwG0>	Mln0V2FPT0WU
human GI-ME-N cell	NUDHdWZVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVrCN482UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NkWzJO69VQ>?	MlPYV2FPT0WU
human GT3TKB cell	NHjzcmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn[5TY5pcWKrdHnvckBw\iCqdX3hckBIXDOWS1KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg6PjR{IN88US=>	M1ns[3NCVkeHUh?=
human CHL-1 cell	M4HBTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmLqTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVI{PzlizszN	M4rpRnNCVkeHUh?=
human CHP-134 cell	M1SzT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH7RTFdKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2xN\|Qh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl2NE[3JO69VQ>?	NHHGO2RUSU6JRWK=
human 8-MG-BA cell	NX;tVXZvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVrJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2PzR2IN88US=>	M1vZZ3NCVkeHUh?=
human HO-1-N-1 cell	M2jBOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37mZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl5MUG3JO69VQ>?	M4\6OnNCVkeHUh?=
human SW1088 cell	M3zBemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIjwT2VKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTl4N{Og{txO	M2T2O3NCVkeHUh?=
human SW48 cell	NWr6UlVRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGfsZlhKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzODZ5IN88US=>	NVzwcJQ2W0GQR1XS
human VM-CUB-1 cell	NYDVSWJwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWfJcohq[mm2aX;uJI9nKGi3bXHuJHZONUOXQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xPDFzOTFOwG0>	M2XzXnNCVkeHUh?=
human COLO-800 cell	Mk[2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFjFcmpKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yNUGzOkDPxE1?	M3P1NHNCVkeHUh?=
human TI-73 cell	NFzS[HZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlLMTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVE{QTlizszN	M3OwcXNCVkeHUh?=
human HN cell	M2Hs[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1Lx[2lvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyNVk5KM7:TR?=	MX\TRW5ITVJ?
human DB cell	MmXrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoLRTY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMUK2N\|Eh\|ryP	M4DreXNCVkeHUh?=
human Ca9-22 cell	M3Xle2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVT1OZZRUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjF{OES3JO69VQ>?	M{DTcXNCVkeHUh?=
human A549 cell	MmXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlzWTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xN\|gxQCEQvF2=	NH72[GlUSU6JRWK=
human KGN cell	MlLsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMkK1PVUh\|ryP	MojuV2FPT0WU
human BCPAP cell	MmDXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2nD[mlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI{OTV6IN88US=>	NGn1NmdUSU6JRWK=
human Ramos-2G6-4C10 cell	NGC3eZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NG\jVZRKdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOzd3OTFOwG0>	MVXTRW5ITVJ?
human OVCAR-5 cell	M4PI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3nJN2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd5M{Sg{txO	M1ywRXNCVkeHUh?=
human KG-1 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlPYTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yO\|c6OiEQvF2=	MoC5V2FPT0WU
human CAKI-1 cell	MnHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVe5d3d7UW6qaXLpeIlwdiCxZjDoeY1idiCFQVvJMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ6MEW4JO69VQ>?	M3rhXHNCVkeHUh?=
human QIMR-WIL cell	Mn7LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXvuZ\|dpUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMki3OFQh\|ryP	M4\hbHNCVkeHUh?=
human SW1710 cell	M2jwZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1LnOWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQTF2MjFOwG0>	NELjfJdUSU6JRWK=
human SK-UT-1 cell	NGLxeZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{DE[GlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjl\|M{mg{txO	NGPtZXpUSU6JRWK=
human IST-SL1 cell	NV;4TI1JT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUTRTphPUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StV2wyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5\|MkG3OEDPxE1?	M{XONHNCVkeHUh?=
human SW962 cell	M3XLOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXO3bFlyUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzN5NUeg{txO	MmKxV2FPT0WU
human EM-2 cell	NGjWbJVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1;oN2lvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|U{OzdizszN	MWTTRW5ITVJ?
human D-263MG cell	NV;5c2RWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlH4TY5pcWKrdHnvckBw\iCqdX3hckBFNTJ4M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDN{NzFOwG0>	MnzZV2FPT0WU
human T98G cell	M4nDOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWKzS2dOUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDh3NzFOwG0>	NYLz[m5oW0GQR1XS
human CTB-1 cell	NGfMOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGfwfFhKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QTd4MTFOwG0>	NFzN[ZVUSU6JRWK=
human Hs-578-T cell	NIHM[2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFHPSJZKdmirYnn0bY9vKG:oIHj1cYFvKEi\|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi52MUW4O{DPxE1?	M1rnN3NCVkeHUh?=
human SF126 cell	NXPBVIxQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmDBTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOFM3OjFizszN	NHf5bFlUSU6JRWK=
human NCI-H460 cell	Mk\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXnSVVVTUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNEO5OVUh\|ryP	NH3iWlVUSU6JRWK=
human NCI-H1755 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NET6TmJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUSwOFMh\|ryP	M3fOcnNCVkeHUh?=
human HL-60 cell	M2LETWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OFE2QSEQvF2=	NXSxe\|BQW0GQR1XS
human G-401 cell	NVHKN\|JlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnPMTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVYxQTlizszN	NHi4XJZUSU6JRWK=
human AGS cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNU[yOVch\|ryP	NECwfY1USU6JRWK=
human HuO9 cell	NF3mRnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2\tZWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWROTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVY1PTZizszN	NXLOflF{W0GQR1XS
human MFE-280 cell	NGr6RolIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\Rb4pQUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53Nk[4OkDPxE1?	MlnFV2FPT0WU
human NCI-H292 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42Pzd{MjFOwG0>	MXjTRW5ITVJ?
human HuO-3N1 cell	MmroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MULJcohq[mm2aX;uJI9nKGi3bXHuJGh2Vy1\|TkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYxOzB5IN88US=>	M1LycHNCVkeHUh?=
human ES3 cell	M1\ObWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml64TY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[yNlg2KM7:TR?=	M2HsXnNCVkeHUh?=
human LB2241-RCC cell	MnjVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZ7MEe5JO69VQ>?	MWTTRW5ITVJ?
human NCI-H1155 cell	M{XCbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2nCNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUSwOUDPxE1?	NHfZd25USU6JRWK=
human SW872 cell	NIjqZmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEnBbpRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44ODZ5NjFOwG0>	M2fYbHNCVkeHUh?=
human MHH-ES-1 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGThdphKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55Mk[zN{DPxE1?	MmS0V2FPT0WU
human KYSE-150 cell	MnfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV3OU\|l5UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwN{K5O{DPxE1?	M3\RfHNCVkeHUh?=
human MC-IXC cell	MoLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFk2OyEQvF2=	NXu0fJpYW0GQR1XS
human HCC1187 cell	NUjWfoZkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4\m[mlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDl4N{eg{txO	NH;IcpNUSU6JRWK=
human UMC-11 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUPJcohq[mm2aX;uJI9nKGi3bXHuJHVOSy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVA1PzdizszN	Mme5V2FPT0WU
human NB5 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4DKUmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj65N\|cyPSEQvF2=	NHPjWJJUSU6JRWK=
human A2058 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkfaTY5pcWKrdHnvckBw\iCqdX3hckBCOjB3ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVc5PDRizszN	NF75cGRUSU6JRWK=
human Becker cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlG1TY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAyOTF{IN88US=>	M37tbnNCVkeHUh?=
human CAS-1 cell	MlXjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NY\lRlNmUW6qaXLpeIlwdiCxZjDoeY1idiCFQWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODF3Nkmg{txO	MnXmV2FPT0WU
human SW780 cell	NG\LeoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fUWmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI2PjB7IN88US=>	MmfjV2FPT0WU
human KM12 cell	M{nxTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoTjTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6zNFE{OiEQvF2=	MVLTRW5ITVJ?
human PC-3 cell	M3HBfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4XBTWlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVc1OTFizszN	M1fvOHNCVkeHUh?=
human A253 cell	NV31SJN4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkXYTY5pcWKrdHnvckBw\iCqdX3hckBCOjV\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xPFg6OyEQvF2=	MYHTRW5ITVJ?
human NB10 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkKyO\|c{KM7:TR?=	Mn3YV2FPT0WU
human A172 cell	M1fUOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0OVch\|ryP	NU\VVGg2W0GQR1XS
human A498 cell	NFu0doxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW2N\|g{KM7:TR?=	NXnOeGVIW0GQR1XS
human SW1573 cell	NFz6dXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEXIN4pKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQTB2OUGg{txO	MoPHV2FPT0WU
human 5637 cell	M{TGSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3z6OGlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuNFc6ODRizszN	NFHvfJlUSU6JRWK=
human A388 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6xN\|k5KM7:TR?=	MWfTRW5ITVJ?
human U251 cell	M1vtW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHH3RXZKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE4yOTd3IN88US=>	MofmV2FPT0WU

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	+ Expand Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

+ Expand

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

+ Expand

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products0

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 8 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 8 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)